Association of sugammadex reversal of neuromuscular block and postoperative length of stay in the ambulatory care facility : a multicentre hospital registry study
Copyright © 2022 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Encapsulation of rocuronium or vecuronium with sugammadex can reverse neuromuscular block faster than neostigmine reversal. This pharmacodynamic profile might facilitate patient discharge after ambulatory surgery.
METHODS: We included patients who underwent ambulatory surgery with general anaesthesia and neuromuscular block between 2016 and 2021 from hospital registries at two large academic healthcare networks in the USA. The primary outcome was postoperative length of stay in the ambulatory care facility (PLOS-ACF). We examined post hoc whether the type of reversal affects postoperative nausea and vomiting and direct hospital costs.
RESULTS: Among the 29 316 patients included, 8945 (30.5%) received sugammadex and 20 371 (69.5%) received neostigmine for reversal. PLOS-ACF and costs were lower in patients who received sugammadex vs neostigmine (adjusted difference in PLOS-ACF: -9.5 min; 95% confidence interval [95% CI], -10.5 to -8.5 min; adjusted difference in direct hospital costs: -US$77; 95% CI, -$88 to -$66; respectively; P<0.001). The association was magnified in patients over age 65 yr, with ASA physical status >2 undergoing short procedures (<2 h) (adjusted difference in PLOS-ACF: -18.2 min; 95% CI, -23.8 to -12.4 min; adjusted difference in direct hospital costs: -$176; 95% CI, -$220 to -$128; P<0.001). Sugammadex use was associated with reduced postoperative nausea and vomiting (17.2% vs 19.6%, P<0.001), which mediated its effects on length of stay.
CONCLUSIONS: Reversal with sugammadex compared with neostigmine was associated with a small decrease in postoperative length of stay in the ambulatory care unit. The effect was magnified in older and high-risk patients, and can be explained by reduced postoperative nausea and vomiting. Sugammadex reversal in ambulatory surgery may also help reduce cost of care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
British journal of anaesthesia - 130(2023), 3 vom: 16. März, Seite 296-304 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azimaraghi, Omid [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2023 Date Revised 24.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bja.2022.10.044 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350476217 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350476217 | ||
| 003 | DE-627 | ||
| 005 | 20231226045103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bja.2022.10.044 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350476217 | ||
| 035 | |a (NLM)36535827 | ||
| 035 | |a (PII)S0007-0912(22)00639-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Azimaraghi, Omid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of sugammadex reversal of neuromuscular block and postoperative length of stay in the ambulatory care facility |b a multicentre hospital registry study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2023 | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Encapsulation of rocuronium or vecuronium with sugammadex can reverse neuromuscular block faster than neostigmine reversal. This pharmacodynamic profile might facilitate patient discharge after ambulatory surgery | ||
| 520 | |a METHODS: We included patients who underwent ambulatory surgery with general anaesthesia and neuromuscular block between 2016 and 2021 from hospital registries at two large academic healthcare networks in the USA. The primary outcome was postoperative length of stay in the ambulatory care facility (PLOS-ACF). We examined post hoc whether the type of reversal affects postoperative nausea and vomiting and direct hospital costs | ||
| 520 | |a RESULTS: Among the 29 316 patients included, 8945 (30.5%) received sugammadex and 20 371 (69.5%) received neostigmine for reversal. PLOS-ACF and costs were lower in patients who received sugammadex vs neostigmine (adjusted difference in PLOS-ACF: -9.5 min; 95% confidence interval [95% CI], -10.5 to -8.5 min; adjusted difference in direct hospital costs: -US$77; 95% CI, -$88 to -$66; respectively; P<0.001). The association was magnified in patients over age 65 yr, with ASA physical status >2 undergoing short procedures (<2 h) (adjusted difference in PLOS-ACF: -18.2 min; 95% CI, -23.8 to -12.4 min; adjusted difference in direct hospital costs: -$176; 95% CI, -$220 to -$128; P<0.001). Sugammadex use was associated with reduced postoperative nausea and vomiting (17.2% vs 19.6%, P<0.001), which mediated its effects on length of stay | ||
| 520 | |a CONCLUSIONS: Reversal with sugammadex compared with neostigmine was associated with a small decrease in postoperative length of stay in the ambulatory care unit. The effect was magnified in older and high-risk patients, and can be explained by reduced postoperative nausea and vomiting. Sugammadex reversal in ambulatory surgery may also help reduce cost of care | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ambulatory care facilities | |
| 650 | 4 | |a healthcare costs | |
| 650 | 4 | |a length of stay | |
| 650 | 4 | |a neostigmine | |
| 650 | 4 | |a neuromuscular block | |
| 650 | 4 | |a postoperative nausea and vomiting | |
| 650 | 4 | |a sugammadex | |
| 650 | 7 | |a Sugammadex |2 NLM | |
| 650 | 7 | |a 361LPM2T56 |2 NLM | |
| 650 | 7 | |a Neostigmine |2 NLM | |
| 650 | 7 | |a 3982TWQ96G |2 NLM | |
| 650 | 7 | |a Cholinesterase Inhibitors |2 NLM | |
| 700 | 1 | |a Ahrens, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Wongtangman, Karuna |e verfasserin |4 aut | |
| 700 | 1 | |a Witt, Annika S |e verfasserin |4 aut | |
| 700 | 1 | |a Rupp, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Suleiman, Aiman |e verfasserin |4 aut | |
| 700 | 1 | |a Tartler, Tim M |e verfasserin |4 aut | |
| 700 | 1 | |a Wachtendorf, Luca J |e verfasserin |4 aut | |
| 700 | 1 | |a Fassbender, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Choice, Curtis |e verfasserin |4 aut | |
| 700 | 1 | |a Houle, Timothy T |e verfasserin |4 aut | |
| 700 | 1 | |a Eikermann, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Schaefer, Maximilian S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of anaesthesia |d 1946 |g 130(2023), 3 vom: 16. März, Seite 296-304 |w (DE-627)NLM000000310 |x 1471-6771 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2023 |g number:3 |g day:16 |g month:03 |g pages:296-304 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bja.2022.10.044 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2023 |e 3 |b 16 |c 03 |h 296-304 | ||